About
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Visit company website
5 years, 6 months ago
XORTX Therapeutics Inc is currently in a long term uptrend where the price is trading 7.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
XORTX Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 222.3% to $-425K since the same quarter in the previous year.
Finally, its free cash flow fell by 1472.2% to $-124K since the same quarter in the previous year.
Based on the above factors, XORTX Therapeutics Inc gets an overall score of 2/5.